Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation  by Ikeda, Kozue & Tachibana, Hideaki
Journal of Arrhythmia 32 (2016) 42–50Contents lists available at ScienceDirectJournal of Arrhythmiahttp://d
1880-42
n Corr
E-mjournal homepage: www.elsevier.com/locate/joaOriginal ArticleClinical implication of monitoring rivaroxaban and apixaban by using
anti-factor Xa assay in patients with non-valvular atrial ﬁbrillation
Kozue Ikeda, MDn, Hideaki Tachibana, MD
Department of Cardiology, Shinoda General Hospital, 2-68 Sakura-cho, Yamagata, Yamagata Prefecture 990-0045, Japana r t i c l e i n f o
Article history:
Received 17 July 2015
Received in revised form
3 August 2015
Accepted 12 August 2015
Available online 15 September 2015
Keywords:
Atrial ﬁbrillation
Direct factor Xa inhibitor
Anti-factor Xa activity
Chromogenic assayx.doi.org/10.1016/j.joa.2015.08.001
76/& 2015 Japanese Heart Rhythm Society. Pu
esponding author. Tel.: þ81 23 623 1711; fax:
ail address: kozue@shinoda-hp.or.jp (K. Ikedaa b s t r a c t
Background: Although patients taking non-vitamin K antagonist oral anticoagulants (NOACs) do not
require routine coagulation monitoring, high-risk patients require monitoring to assess pharmacody-
namics.
Methods: We measured (1) anti-factor Xa activity (AXA), using chromogenic assay with the HemosIL
Liquid Heparin kit, (2) prothrombin time (PT), and (3) activated partial thromboplastin time (aPTT) in 188
blood samples from 70 patients with non-valvular atrial ﬁbrillation, of whom 36 received rivaroxaban
once daily and 34 received apixaban twice daily.
Results: After the rivaroxaban therapy, AXA ranged from 0 to 3.65 IU/mL; PT, from 9.6 to 44.5 s; and APTT,
from 19.3 to 69.7 s. After the apixaban therapy, AXA ranged from 0.02 to 3.18 IU/mL; PT, from 10.2 to
20.8 s; and APTT, from 21.8 to 59.8 s. At peak time, the AXA of patients who received rivaroxaban and
apixaban were almost the same (2.0870.91 IU/mL vs. 1.7170.57 IU/mL), but the PT and APTT of patients
who received rivaroxaban were more prolonged than those of patients who received apixaban
(18.175.6 s vs. 13.870.9 s, po0.001 and 40.977.3 s vs. 35.577.5 s, po0.01, respectively). At trough
time, the AXA and PT of patients who received rivaroxaban were respectively lower and shorter than
those of patients who received apixaban (0.2870.31 IU/mL vs. 1.0470.72 IU/mL, po0.001 and
11.972.0 s vs. 13.772.4 s, po0.01, respectively), but the APTT of patients who received rivaroxaban and
apixaban did not signiﬁcantly differ (32.374.3 s vs. 34.373.8 s).
Conclusions: Measurement of AXA might be useful to assess the pharmacodynamics of high-risk patients,
such as high age, low body weight, and/or low renal function, and to assess the intensity of antic-
oagulation by using different methods of administration, such as crushed tablet via the nasogastric tube.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Administration of non-vitamin K antagonist oral anticoagulants
(NOAC) is convenient, as they do not require routine coagulation
monitoring. However, in patients with low renal function or old age,
monitoring to assess pharmacodynamics and to avoid intracranial
hemorrhage or major bleeding due to overdose is needed. Anti-
factor Xa chromogenic assay has been proved to have excellent
linearity with the plasma concentration of direct anti-factor Xa
inhibitors [1–5]. It has been used for measurement of the intensity
of anticoagulation and for drug quantiﬁcation in patients receiving
direct anti-factor Xa inhibitors [6–8]. The HemosIL Liquid Heparin
kit (Instrumentation Laboratory, Bedford, Massachusetts, USA) is an
Xa-dependent chromogenic assay and can measure unfractionated
and low-molecular-weight heparins, and direct and indirect Xa
inhibitors [9,10]. Because it is approved for the measurement ofblished by Elsevier B.V. All rights
þ81 23 625 2400.
).blood heparin concentration by the Public Medical Insurance, the
HemosIL Liquid Heparin kit is more accessible than other anti-factor
Xa assay kits in Japan.
Large clinical trials [11–14] were performed to assess the efﬁ-
cacy and safety of NOACs, but the percentage of patients with low
renal function in these studies was relatively smaller than that in
real-world data. The aim of this study was to examine the impli-
cation of monitoring the direct factor Xa inhibitors rivaroxaban
[11,12] and apixaban [13,14] by performing an anti-factor Xa assay
using the HemosIL Liquid Heparin kit in a clinical population of
elderly patients with low renal function.2. Materials and methods
2.1. Subjects
The subjects were 70 patients with non-valvular atrial ﬁbrilla-
tion, of whom 36 received rivaroxaban once daily and 34 receivedreserved.
Fig. 1. Principles of anti-factor Xa assay using the HemosIL Liquid Heparin kit. Comparison between heparin assay (a) and anti-factor Xa assay (b). Revised with permission
from the pamphlet of HemosIL Liquid Heparin kit in Japanese. (a) Principles of Heparin Assay. and ,(b) Principles of anti-factor Xa Assay.
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according to the physician's decision. Written informed consent was
obtained from the patients or their next of kin. This study was
approved by the institutional review board of Shinoda General
Hospital (approval no. 20120725-4) on July 25, 2012, and conducted
in accordance with The Code of Ethics of the World Medical Asso-
ciation (Declaration of Helsinki).
The rivaroxaban dosage was chosen according to the recom-
mended regimen in Japan, which is 15 mg once daily for patients
with creatinine clearance (CCr) Z50 mL/min and 10 mg once daily
for patients with CCro50 mL/min. Rivaroxaban was contraindicated
in patients with CCro15 mL/min. The apixaban dosage was also
chosen according to the recommended regimen, which is 5 mg twice
daily for patients with 1 of the following 3 characteristics or lower
values than those indicated in the following: age Z80 years, body
weight r60 kg, and serum creatinine level Z than 1.5 mg/dL, and
2.5 mg twice daily for patients with at least 2 of the 3 characteristics.
Apixaban was contraindicated in patients with CCro15 mL/min.
2.2. Measurements of anti-factor Xa activity, PT, and APTT
We measured anti-factor Xa activity by performing a chro-
mogenic assay by using the HemosIL Liquid Heparin kit [6,7](Instrumentation Laboratory), PT (RecombiPlasTin; HemosIL,
Instrumentation Laboratory), and aPTT (SynthASil; HemosIL,
Instrumentation Laboratory) in 188 blood samples from the 70
subjects. The blood samples were collected in 3.2% sodium citrate
tubes. Anti-Xa activity, PT, and APTT were measured by using the
analyzer system ACL TOP 500 CTS (Instrumentation Laboratory).
The principle of the anti-factor Xa assay is shown in Fig. 1.
The anti-factor Xa activity measurement was expressed as
heparin activity (IU/mL). The plasma concentration of rivarox-
aban was also estimated by using the following formula:
1 IU/mL¼225 ng/mL [10].2.3. Statistical analysis
Continuous variables were expressed as mean7SD. Categorical
variables were presented as numbers. A statistical comparison was
performed by using the Student t test or Wilcoxon signed-rank
test for the continuous variables, the chi-square test or Fisher
exact test for the categorical variables, and the Pearson product-
moment correlation analysis. Two-sided po0.05 was considered
statistically signiﬁcant.
Table 2a
Anti-factor Xa activity, PT, and APTT of all data.
Rivaroxaban Apixaban p Value
Samples 98 90
Anti-factor Xa activity
(IU/mL)
0.00–3.65
(1.2071.05)
0.02–3.18
(1.1270.79)
NS
Rivaroxaban concentra-
tion (ng/mL)
0.0–821.3
(269.67237.3)
PT (s) 9.6–44.6 (15.574.7) 10.2–20.8
(13.172.2)
o0.001
APTT (s) 19.3–69.7
(39.077.9)
21.8–59.8
(34.475.1)
o0.001
(mean7SD)
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3.1. Clinical characteristics of the subjects
The clinical characteristics of the patients are shown in Table 1.
The 36 patients who received rivaroxaban once daily were 35–97
years old and had CCr of 33.0–134.3 mL/min. The 34 patients who
received apixaban twice daily were 61–97 years old and had CCr of
16.2–95.4 mL/min. The patients who received apixaban were
older, had lower body weights, lower body mass indexes, lower
CCr, higher CHADS2 and CHA2DS2-VASc scores, and higher per-
centage of patients with reduced dose than those who received
rivaroxaban, indicating signiﬁcant differences. No signiﬁcant dif-
ferences were observed between the rivaroxaban and apixaban
groups in the use of angiotensin II receptor blockers, angiotensin-
converting enzyme inhibitor, antiarrhythmic drugs, Na channel
blockers, amiodarone, beta blockers, statin, antiplatelets, P glyco-
protein inhibitors, and past use of warfarin, as well as NOACs. Only
the use of aldosterone blockers was signiﬁcantly higher in the
patients who received apixaban (32%) than in those who received
rivaroxaban (8%).
3.2. Anti-factor Xa activity, PT, and APTT
Blood sample measurements were performed 7–911 days
(mean7SD: 2297231 days) after the ﬁrst administration of riv-
aroxaban, and 7–378 days (83790 days) after the ﬁrst adminis-
tration of apixaban. The measured parameters are summarized in
Table 2a. In the patients who received rivaroxaban, the anti-factor
Xa activity ranged from 0 to 3.65 IU/mL; the estimated plasma
concentration of rivaroxaban, from 0 to 821.3 ng/mL (269.67
237.3 ng/mL); PT, from 9.6 to 44.5 s; and APTT, from 19.3 to 69.7 s.
In the patients who received apixaban, the anti-factor Xa activity
ranged from 0.02 to 3.18 IU/mL; PT, from 10.2 to 20.8 s; and APTT,Table 1
Clinical characteristics of the subjects.
Rivaroxaban Apixaban p Value
Patients 36 34
Male/female 22/14 13/21 NS
Paroxysmal/chronic 16/20 16/18 NS
Age (years), range (mean7SD) 35–97
(74.1713.9)
61–97
(82.9710.3)
o0.01
Body weight (kg) 34.5–82.0
(60.3711.7)
34.0–73.2
(49.178.7)
o0.001
Body mass index (kg/m2) 17.6–28.8
(23.672.5)
16.5–26.6
(21.172.7)
o0.001
Cr (mg/dL) 0.45–1.48
(0.8270.27)
0.45–1.39
(0.8770.22)
NS
CCr (mL/min) 33.0–134.3
(69.0726.6)
16.2–95.4
(44.5719.9)
o0.001
CHADS2 score 0–5 (2.171.3) 1–5 (3.271.1) o0.001
CHA2DS2-VASc score 0–7 (3.471.9) 1–7 (4.971.4) o0.001
Normal dose/reduced dose 22/14 9/25 o0.01
Medication
ARB 16 (44%) 16 (44%) NS
ACE-I 5 (14%) 8 (24%) NS
Aldosterone blockers 3 (8%) 11 (32%) o0.05
Antiarrhythmic drugs 10 (28%) 7 (21%) NS
Na channel blockers 9 (25%) 3 (9%) NS
Amiodarone 1 (3%) 4 (12%) NS
Beta blockers 19 (53%) 18 (53%) NS
Statin 4 (11%) 8 (24%) NS
Antiplatelets 1 (3%) 3 (9%) NS
P glycoprotein inhibitors 5 (14%) 4 (12%) NS
Past use of warfarin 13 (36%) 9 (27%) NS
Past use of other NOACs 8 (22%) 4 (12%) NS
Blood samples 98 90from 21.8 to 59.8 s. The mean values of anti-factor Xa activity did
not signiﬁcantly differ between ribaroxaban and apixaban
(1.2071.05 IU/mL vs. 1.1270.79 IU/mL). However, PT and APTT
were signiﬁcantly longer in the rivaroxaban group than in the
apixaban group (PT: 15.574.7 s vs. 13.172.2 s, po0.001; APTT:
39.077.9 s vs. 34.475.1 s, po0.001).
Fig. 2 shows the plot for anti-factor Xa activity, and PT and APTT
against the times after the administration of rivaroxaban and
apixaban. For both drugs, the peak of the anti-factor Xa was
observed around 2–5 h after administration. For rivaroxaban, small
PT and APTT peaks were also observed. However, for apixaban,
peaks were not clear both in PT and in APTT.
Fig. 3 shows the plot for anti-factor Xa activity, and PT and APTT
against the times after the administration of rivaroxaban and
apixaban for normal and reduced doses. For both drugs, the
reduced dose was chosen according to the recommended regimen
in Japan. In the patients who received rivaroxaban, the anti-factor
Xa activities of the normal dose (15 mg once daily) and reduced
dose (10 mg once daily) seemed to be on the same time-activity
curve. Also, in the patients who received apixaban, the anti-factor
Xa activities of the normal dose (5 mg twice daily) and reduced
dose (2.5 mg twice daily) seemed to be on the same time-activity
curve. Relatively high anti-factor Xa activity was observed at
trough time in several patients who received 2.5-mg apixaban
twice daily. Relatively high anti-factor Xa activity was observed in
patients with CCro30 mL/min. Anti-factor Xa activity 42.5 IU/mL
at trough time was observed in patients with CCro20 mL/min.
Apparent differences in PT and APTT were not found between the
normal and reduced doses of both drugs.
Table 2b shows the anti-factor Xa activity, PT, and APTT at peak
time, 2–5 h after the administration of both drugs, trough time,
20–26 h after the administration of rivaroxaban, and 10–14 h after
the administration of apixaban. In the patients who received riv-
aroxaban, anti-factor Xa activity, rivaroxaban concentration, PT,
and APTT at peak time were signiﬁcantly greater than those at
trough time (po0.001, po0.001, po0.001, and po0.001,
respectively). However, in the patients who received apixaban, the
anti-factor Xa activity at peak time was signiﬁcantly greater than
that at trough time (po0.01), and the PT and APTT at peak time
were not signiﬁcantly prolonged than those at trough time.
At peak time, the anti-factor Xa activities of rivaroxaban and
apixaban were almost the same (2.0870.91 IU/mL vs. 1.717
0.57 IU/mL), but the PT and APTT of rivaroxaban were more pro-
longed than those of apixaban (PT: 18.175.6 s vs. 13.870.9 s,
po0.001; APTT: 40.977.3 s vs. 35.577.5 s, po0.01). At trough
time, the anti-factor Xa activity of rivaroxaban was lower than that
of apixaban (0.2870.31 IU/mL vs. 1.0470.72 IU/mL, po0.001).
The PT of rivaroxaban was shorter than that of apixaban
(11.972.0 s vs. 13.772.4 s, po0.01). However, the APTTs of riv-
aroxaban and apixaban were not signiﬁcantly different (32.37
4.3 s vs. 34.373.8 s).
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Fig. 2. Anti-factor Xa activity (a), prothrombin time (b), and activated partial
thromboplastin time (c) in relation to the time after administration of rivaroxaban
and apixaban. The blue points indicate the values for rivaroxaban, and the red
points indicate the values for apixaban.
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Fig. 4 shows the plot for PT or APTT against the anti-factor Xa
activities of rivaroxaban and apixaban. In the patients who
received rivaroxaban, PT was prolonged in proportion to theincrease in anti-Xa activity, but the change in PT was small and
much overlapped. In the patients who received apixaban, PT was
slightly prolonged in proportion to the increase in anti-Xa activity,
but signiﬁcant prolongation of PT was observed only when the
anti-Xa activity was very high.
In the patients who received rivaroxaban, APTT tended to be
prolonged as the anti-Xa activity increased but much more over-
lapped than PT. In the patients who received apixaban, APTT
tended to be slightly prolonged as the anti-Xa activity increased
but much more overlapped than in that in patients who received
rivaroxaban.
3.4. Relationship of anti-factor Xa activity, PT, and APTT to CCr
Fig. 5a shows the relationship between the anti-factor Xa
activity and CCr of rivaroxaban and apixaban. The relationship of
PT or APTT to CCr are shown in Fig. 5b and c. Data were plotted in
different colors according to blood sampling time as follows: peak
time, 2–5 h after the administration of both drugs; trough time, 20
to 26 h after the administration of rivaroxaban and 10–14 h after
the administration of apixaban; and intermediate time, other than
peak or trough time. The graph in Fig. 5 demonstrates the inﬂu-
ence of time after administration on the relationship of CCr to
anti-factor Xa activity, PT, or APTT.
In the patients who received rivaroxaban, the anti-factor Xa
activity at peak time tended to increase as the CCr decreased, but
that at trough time did not increase as the CCr decreased. Thus, no
signiﬁcant correlation was found between anti-factor Xa activity
and CCr (r¼0.089, NS), between PT and CCr (r¼0.031, NS), nor
between APTT and CCr (r¼0.026, NS). In the patients who
received apixaban, the anti-factor Xa activity at peak time tended to
increase as the CCr decreased, and that at trough time also
increased when the CCr decreased severely to o20 mL/min. A
signiﬁcant correlation was found between anti-factor Xa activity
and CCr (r¼0.439, po0.01), and between PT and CCr (r¼0.427,
po0.01), but not between APTT and CCr (r¼0.101, NS).
Except at trough time, the anti-factor Xa activity of rivaroxaban
tended to be higher than that of apixaban, in the comparison
between the patients with same degree of CCr. Anti-factor Xa
activity 42.5 IU/mL was frequently observed in the rivaroxaban
patients with CCro50 mL/min and in the apixaban patients with
CCro30 mL/min. Anti-factor Xa activity was 43.0 IU/mL in
5 patients (4 patients taking rivaroxaban and 1 patient taking
apixaban), in 3 patients at peak time (all taking rivaroxaban), and
in 2 patients after peak time (1 taking rivaroxaban and 1 taking
apixaban). The 2 patients with very high anti-factor Xa activity
after peak time (cases A and B) were quite elderly.
3.5. Case presentations
3.5.1. Cases with high anti-factor Xa activity
Case A (Table 3a) was a 97-year-old female patient who had been
taking 10-mg rivaroxaban once daily, had paroxysmal atrial ﬁbril-
lation, and had artiﬁcial cardiac pacemaker implantation for a sec-
ond-degree AV block. Her body weight was 42.5 kg; CCr, 47.9 mL/
min; CHADS2 score, 3; and CHA2DS2-VASc score, 5. The anti-factor
Xa activity at 6.5 h after administration was 3.48 IU/mL. The rivar-
oxaban concentration was 783 ng/mL, more than 3 times higher
than the normal curve [15]. Although no clinical sign of hemorrhage
was observed, rivaroxaban was changed to 2.5-mg apixaban twice
daily according to the physician's decision. After the change to
apixaban, the anti-factor Xa activity was 1.42 IU/mL at 5.5 h after the
administration of apixaban and CCr was 49.0 mL/min.
Case B (Table 3b) was a 90-year-old female patient who had
been taking 2.5-mg apixaban twice daily, had paroxysmal atrial
ﬁbrillation, and had histories of myocardial infarction, congestive
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Fig. 3. Effects of normal and reduced doses on anti-factor Xa activity in rivaroxaban (a) and apixaban (b), and on PT (c) and APTT (d). For rivaroxaban, the blue points indicate
the normal dose (15 mg once daily) and the gray points indicate the reduced dose (10 mg once daily). For apixaban, the red points indicate the normal dose (5 mg twice
daily) and the yellow points indicate the reduced dose (2.5 mg twice daily). The ﬁgure shows the values obtained within 30 h after the administration of the drugs
(rivaroxaban, 98 samples; apixaban, 88 samples), 2297231 days after the ﬁrst administration of rivaroxaban, and 83791 days after the ﬁrst administration of apixaban. For
rivaroxaban and apixaban, the anti-factor Xa activity of the normal and reduced doses seemed to be on the same time–activity curve. Apparent differences in PT and APTT
were not found between the normal and reduced doses of both drugs.
Table 2b
Anti-factor Xa activity, PT, and APTT at peak and trough times.
Rivaroxaban Apixaban
Peak time (2–5 h) Trough time (20–26 h) Peak time (2–5 h) Trough time (10–14 h)
Samples 42 23 19 19
Anti-factor Xa activity (IU/mL) 0.44–3.65 (2.0870.91**) 0.00–1.29 (0.2870.31##) 0.83–2.77 (1.7170.57*) 0.22–2.86 (1.0470.72)
Rivaroxaban concentration (ng/mL) 99.0–821.3 (467.37204.2**) 0.0–290.3 (62.5770.6)
PT (s) 12.2–44.6 (18.175.6**##) 10.1–18.6 (11.972.0#) 11.9–15.4 (13.870.9) 11.0–17.9 (13.772.4)
APTT (s) 32.1–69.7 (40.977.3**#) 19.3–38.0 (32.374.3) 22.0–59.8 (35.577.5) 27.7–42.1 (34.373.8)
(mean7SD)
* po0.01, vs. trough time.
** po0.001, vs. trough time.
# po0.01, vs. apixaban.
## po0.001, vs. apixaban.
K. Ikeda, H. Tachibana / Journal of Arrhythmia 32 (2016) 42–5046heart failure, and chronic renal failure. Before treatment with
apixaban, CCr was 24.4 mL/min. After treatment with 2.5-mg
apixaban twice daily, anti-factor Xa activity was 3.18 IU/mL at 12 h
after administration and the CCr decreased to 16.5 mL/min. After
dose adjustment to 2.5 mg of apixaban once daily, the anti-factor
Xa activity at trough time was 1.79 IU/mL. At 1.5 months after, the
CCr decreased to 6.0 mL/min because of decreased renal function
from the congestive heart failure. Apixaban was given at 2.5 mg
once every other day, and the anti-factor Xa activity at trough timewas 2.53 IU/mL. As the CCr decreased under contraindication level,
apixaban administration was discontinued. For cases of severe
chronic renal failure such as those with CCr of 15–20 mL/min, 2.5-
mg apixaban once daily, not 2.5-mg apixaban twice daily, might be
considered as one of the treatment option.
Case C (Table 3c) was a 94-year old female patient who had been
taking 2.5-mg apixaban twice daily, had chronic atrial ﬁbrillation,
chronic cardiac failure from hypertensive heart disease, and chronic
renal failure. Her body weight was 48.2 kg, CCr was 28.1 mL/min,
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Fig. 4. The relationship of PT (a) and APTT (b) to the anti-factor Xa activity in
rivaroxaban and apixaban. The blue points indicate the values for rivaroxaban, and
the red points indicate the values for apixaban.
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day of treatment, anti-factor Xa activity was 2.77 IU/mL at 4 h after
administration (peak) and 1.74 IU/mL at 12 h after administration
(trough time). At peak time, PT (14.6 s) and APTT (39.3 s) were
mildly prolonged. At trough time, PT (12.9 s) and APTT (37.5 s) were
not prolonged and CCr was 32.7 mL/min. The apixaban dosage was
changed to 2.5-mg once daily.
Two weeks after, anti-factor Xa activity was 0.35 IU/mL at 4 h
after administration (peak time) and 0.37 IU/mL at 22 h after
administration (trough time). The apixaban dose was returned to
2.5 mg twice daily. Two weeks after, anti-factor Xa activity was
2.16 IU/mL at 4 h after administration (peak time) and 1.35 IU/mL
at 22 h after administration (trough time). In this case of slightly
severe renal failure, with CCr of 25–35 mL/min, 2.5-mg apixaban
twice daily was needed to maintain anti-factor Xa activity.
3.5.2. A case of administration of crushed tablet via a nasogastric
tube
Anti-factor Xa assay might be also useful to assess the intensity of
anticoagulation by using different methods of administration such as
crushed tablet via a nasogastric tube. Case D (Table 3d) was an 83-
year-old male patient who had been taking 10 mg of crushed rivar-
oxaban tablet once daily via a nasogastric tube, and had chronic atrial
ﬁbrillation and cardiogenic cerebral embolism. His body weight was
39.7 kg, CCr was 48.3 mL/min, CHADS2 score was 4, and CHA2DS2-
VASc score was 5. At 4 h after administration, anti-factor Xa activitywas 0.71 IU/mL, and the rivaroxaban concentrationwas 159.75 ng/mL,
about half of the normal curve [12]. At 22 h after administration, anti-
factor Xa activity was 0 IU/mL and the rivaroxaban concentration was
0 ng/mL. The altered method of administration of crushed tablet via a
nasogastric tube might have affected drug absorption.4. Discussion
4.1. Anti-factor Xa activity of rivaroxaban and apixaban
We measured anti-factor Xa activity, PT, and aPTT in 188 blood
samples from 70 patients with non-valvular atrial ﬁbrillation, of
Table 3a
Clinical course of case A.
CCr
(mL/
min)
Rivaroxaban
(ng/mL)
Anti-factor Xa
activity
(IU/mL)
PT (s) APTT (s)
Rivaroxaban
10 mg once
daily (6.5 h
after)
47.9 783.0 3.48 23.8 38.2
Apixaban
2.5 mg twice
daily (5.5 h
after)
49.0 – 1.42 14.8 30.9
Table 3b
Clinical course of case B.
CCr (mL/
min)
Anti-factor Xa
activity (IU/mL)
PT (s) APTT (s)
Before 24.4 – 11.0 33.3
Apixaban (trough)
(14th day) 2.5 mg twice
daily
16.5 3.18 19.4 40.3
(22nd day) 2.5 mg once
daily
17.0 1.79 14.9 37.9
(36th day) 2.5 mg once
daily
15.1 1.73 14.9 38.3
(53rd day) 2.5 mg once for
every other day
6.0 2.53 16.4 41.8
Table 3c
Clinical course of case C.
CCr (mL/
min)
Anti-factor Xa activ-
ity (IU/mL)
PT (s) APTT (s)
Before 28.1 – 10.3 34.2
Apixaban
(14th day) 2.5 mg twice
daily peak
32.7 2.77 14.6 39.3
2.5 mg twice daily
trough
1.74 12.9 37.5
(28th day) 2.5 mg once
daily peak
27.9 0.35 11.5 33.1
2.5 mg once daily
trough
0.37 11.6 36.6
(42nd day) 2.5 mg twice
daily peak
33.7 2.16 14.0 36.1
2.5 mg twice daily
trough
1.35 12.9 36.1
Table 3d
Clinical course of case D.
Rivaroxaban concentration (ng/mL) Anti-factor Xa
activity (IU/mL)
PT (s) APTT (s)
Rivaroxaban
10 mg of crushed tablet
4 h after 159.75 0.71 21.9 42.8
22 h
after
0.00 0.00 14.7 36.0
K. Ikeda, H. Tachibana / Journal of Arrhythmia 32 (2016) 42–5048whom 36 received rivaroxaban once daily and 34 received apix-
aban twice daily. The study subjects were older than the subjects
of large clinical trials [11–14].In this study, anti-factor Xa activity measurements were
expressed as heparin activity (IU/mL) and converted to plasma
concentration of rivaroxaban by using the conversion formula [10].
Estimation of plasma drug concentration was convenient in the
assessment of pharmacodynamics in individual patients, as in
cases A and D. The plasma concentration of apixaban could also be
estimated by using other chromogenic assay kits [5,6]. The con-
version formula for apixaban in the HemosIL Liquid Heparin kit
must be established.
Meanwhile, anti-factor Xa activity expressed in IU/mL was useful
in the comparison between the treatment effects of rivaroxaban
and apixaban [6]. Thus, we mainly used anti-factor Xa activity
(IU/mL) in this study. For both drugs, the peak of the anti-factor Xa
was observed around 2–5 h after administration. The Tmax of riv-
aroxaban on repetitive administration in healthy aged Japanese
men and women was reported to be 1.0–4.0 h (median for 15 mg
once daily, 3.5 h) and 1.5– 4.0 h (median for 10 mg once daily 3.0 h)
[15]. The Tmax of apixaban on repetitive administration in healthy
Japanese men was reported to be 3.0–4.0 h (median for 5 mg twice
daily, 3.5 h) and 1.0–4.0 h (median for 2.5 mg twice daily, 2.0 h)
[16]. Our data were almost comparable with these data.
In most patients, the anti-factor Xa activities of plasma rivar-
oxaban and apixaban were within the acceptable range of antic-
oagulation. Both for rivaroxaban and apixaban, the anti-factor Xa
activities of the normal and reduced doses seemed to be on the
same time-activity curve. The dosage regimens of 15 mg once daily
or 10 mg once daily of rivaroxaban, and 5 mg twice daily or 2.5 mg
twice daily of apixaban were thought to be acceptable based on
our study results.
The differences in anti-factor Xa activity between the peak and
trough times were greater in rivaroxaban than in apixaban, corre-
sponding to the difference in dosage, that is, once daily to twice daily
[6]. At peak time, the PT of rivaroxabanwas more prolonged than that
of apixaban (18.175.6 s vs. 13.870.9 s), although anti-Xa activity
was almost the same (2.0870.91 IU/mL vs. 1.7170.57 IU/mL).
4.2. PT and APTT
In the patients who received rivaroxaban, the PT at peak time
was longer than that at trough time (18.175.6 s vs. 11.972.0 s).
The PT was prolonged in proportion to the increase in anti-Xa
activity, but the change in PT was small and much overlapped. In
the patients who received apixaban, PT was slightly prolonged in
proportion to the increase in anti-Xa activity but signiﬁcantly
prolonged only when anti-Xa activity was very high.
In both drugs, the prolongation of PT was too small to be used
as a clinical index to assume the intensity of anticoagulation.
Barrett el al. [7] demonstrated that an anti-factor Xa assay was
preferable to PT. In the patients who received rivaroxaban and
apixaban, APTT tended to be prolonged but much overlapped.
APTT was not suitable for use as a clinical marker of antic-
oagulation of direct factor Xa inhibitors [1,4,5].
Our results coincide well with the results of the recent sys-
tematical review by Cuker et al. [17]. They reviewed studies that
assessed relationships of drug levels of dabigatran, rivaroxaban,
and apixaban to coagulation assay results. They concluded that for
rivaroxaban and apixaban, anti-Xa activity was linear over a wide
range of drug levels and may be used for drug quantiﬁcation.
However, PT was less sensitive, especially for apixaban. A normal
PT may not exclude clinically relevant levels. APTT demonstrated
insufﬁcient sensitivity and linearity for quantiﬁcation [17].
4.3. CCr and anti-factor Xa activity
In the patients who received apixaban, anti-factor Xa activity
tended to be higher as CCr decreased. A signiﬁcant correlation was
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tioned that in the patients who received apixaban, the anti-factor
Xa activity at trough time might have increased with the severe
decrease in CCr to o20 mL/min. However, in the patients who
received rivaroxaban, a signiﬁcant correlation was not found
between anti-factor Xa activity and CCr. This difference might be
related to the greater decrease in anti-factor Xa activity at trough
time in the patients who received rivaroxaban than in the patients
who received apixaban.
In comparison of the patients with the same degree of CCr, the
anti-factor Xa activity of rivaroxaban, except at trough time, ten-
ded to be higher than that of apixaban. Anti-factor Xa
activity42.5 IU/mL was frequently observed in the patients who
received rivaroxaban and had CCro50 mL/min, and in the
patients who received apixaban and had CCro30 mL/min. Mon-
itoring anti-factor Xa activity might be beneﬁcial to patients who
receive rivaroxaban and have CCro50 mL/min and to patients
who receive apixaban and have CCro30 mL/min.
As for apixaban, in the patients with slightly severe renal fail-
ure with CCr of 25–35 mL/min, 2.5 mg twice daily was needed to
maintain anti-factor Xa activity. However, in the patients with
more severe renal failure with CCr of 15–20 mL/min, 2.5 mg once
daily, not 2.5 mg twice daily, might be considered as a treatment
option. In the patients with super-high age, low body weight, and
severe renal dysfunction, the clinical safety and beneﬁt of NOACs
have not been established yet. In such patients, warfarin may still
be safer than NOACs. However, Jun et al. [18] reported that among
older adults with atrial ﬁbrillation starting warfarin administra-
tion, those with reduced kidney function with an estimated glo-
merular ﬁltration rate o15 mL/min/1.73 m2 were associated with
3.5-fold greater gastrointestinal bleeding during the ﬁrst 30 days
of treatment.
It is possible that with the use of anti-factor Xa assay, direct
factor Xa inhibitors can be used more safely in patients with super-
high age, low body weight, and/or low renal function. The ther-
apeutic range of anti-factor Xa activity must be established in
patients receiving rivaroxaban and apixaban.
4.4. Assessment of the intensity of anticoagulation in the altered
method of administration
Anti-factor Xa activity was lower in the patients who received
crushed rivaroxaban tablet via nasogastric tube. The altered
method of administration might have affected drug absorption. A
previous study reported that the Cmax of rivaroxaban decreased to
56% when rivaroxaban granulate was released in the proximal
small intestine [19]. Okada et al. demonstrated that the estimated
plasma concentration of rivaroxaban by anti-factor Xa assay in
patients who received crushed tablets via a nasogastric tube was
72% lower at 4 h and 70% lower at 9 h [8].
4.5. Limitations of this study
The study patients were not randomized to receive either riv-
aroxaban or apixaban. Because the drug selection depended on the
physician's decision, the patients who received apixaban were
signiﬁcantly older, and had lower body weight, lower CCr, higher
CHADS2 score, and CHA2DS2-VASc score than the patients who
received rivaroxaban. Blood sampling was performed in clinical
situations. We did not perform multiple serial sampling after
administration. Hence, the accurate peak time of anti-factor Xa
activity or the peak value of anti-factor Xa activity could not be
determined from this study. The patient populations were also
small. A larger multicenter study must be conducted to establishthe therapeutic range of the anti-factor Xa activities of rivaroxaban
or apixaban.5. Conclusion
Measurement of anti-factor Xa activity by using the HemosIL
Liquid Heparin kit might be useful to assess the pharmacody-
namics of high-risk patients, such as those with high age, low body
weight, and/or low renal function, and to assess the intensity of
anticoagulation by using different methods of administration, such
as crushed tablet via a nasogastric tube.Conﬂict of interest
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